RESUMO
Objective Fibronectin 1 (FN1) is a glycoprotein involved in cellular adhesion and migration processes. The aim of this study was to investigate the expression and clinicopathological significance of FN1 in gastric cancer and to predict the possible mechanism of FN1. Methods GEO data and TCGA data were downloaded. FN1 expression in gastric cancer and adjacent tissues was analyzed by GSE54129 data, and then verified by GSE29272 and TCGA data. According to the expression profile data and FN1 expression, mRNA expression value was divided into low expression(<-0.475), and medium expression(-0.475~1.036), high expression (>1.036). FN1 expression in gastric cancer and clinicopathological relationship were analyzed. TCGA data and Kaplan Meier were used to analyze the relationship between the expression level of FN1 and the prognosis of gastric cancer patients; while gene concentration analysis (GSEA) was used to predict the related path of FN1. Results TCGA data showed the medium survival time of low, medium, high FN1 expression was respectively 63.5, 55.7, 39.4 months, and the difference between low expression and high expression in survival time was of statistical significance. Kaplan Meier Plotter online data analysis showed the medium survival time of FN1 high expression was shorter than that of low expression(P<0.01), which meant the higher the FN1 expression was, the worse the prognosis was. FN1 expression is an independent prognostic factor (HR=0.480,95% CI:0.336~0.686). High expression of FN1 samples enriched gene sets such as KRAS (FDR=0.052), P53(FDR=0.052), TGF-β(FDR=0.052), cell adhesion(FDR=0.0), extracellular matrix (FDR=0.043)and cytoskeletal protein regulation (FDR=0.052). Conclusion The high expression of FN1 is a poor prognostic factor for gastric cancer and can be used as an effective biomarker for predicting the metastasis and prognosis of gastric cancer. High expression of FN1 leads to abnormalities in KRAS, P53, TGF-β, ECM, cell adhesion and cytoskeletal protein regulatory pathways.
RESUMO
Objective Prognoses of late stage signet-ring cell carcinoma (SRCC) is usually worse than that in other gastric carcinoma. In the current study, SEER database were adopted to analyze the clinicopathologic features and prognoses of SRCC and non-signet-ring cell carcinoma (non SRCC), and to compare the differences in survival rate under different early treatments. Methods Clinical data of 5193 patients who were diagnosed with gastric carcinoma from 2010 to 2015 are collected from SEER. Patients are divided into two groups SRCC (n=2439) and non SRCC (n=2754) based on their histologic type. Differences in Gender, age, race, primary site, degree of differentiation, tumor size, depth of invasion, local lymph node metastasis, distant metastasis, tumor, node, metastasis (TNM) staging, operative treatment and chemotherapy were compared. Cox regression model was used to analyze prognostic factors. According to different operative treatment, patients in SRCC and non SRCC groups were divided into surgery group and surgery with adjuvant chemotherapy group, respectively. Kaplan-meier method was used to draw the survival curve, and Log-Rank test was adopted for survival analysis. Results Significant statistical difference (P<0.05) were found in the two gastric carcinoma groups regarding gender, age, race, primary site, degree of differentiation, tumor size, depth of invasion, local lymph node metastasis, distant metastasis, TNM staging, operative treatment and chemotherapy. The multivariate Cox regression analysis indicated that age (HR:1.417; 95%CI:1.273-1.578; P<0.05), race (HR:0.91; 95%CI:0.825-0.998; P<0.05), tumor size (HR:1.28; 95%CI: 1.199-1.365; P<0.05), depth of invasion (HR: 1.252: 95%CI: 1.159-1.352; P<0.05), local lymph node metastasis (HR:0.862; 95%CI: 0.81-0.918; P<0.05), distant metastasis (HR: 1.369: 95%CI: 1.069-1.753; P<0.05), TNM stage (HR:1.342; 95%CI:1.155-1.559; P<0.05), and surgical treatment (HR:0.245; 95%CI: 0.228-0.284; P<0.05) are independent risk factors affecting the prognosis of SRCC patients. The overall five-year survival rate of SRCC patients is 27.6% , which is lower than that of non SRCC patients (43.0%). Therefore, there is significant difference in statistics (P<0.05). Significant statistical difference was also found in stratification analysis of the five-year survival rates among SRCC surgery group, SRCC surgery with adjuvant chemotherapy group, non SRCC surgery group and non SRCC surgery with adjuvant chemotherapy group. The results indicated that the five-year survival rates of SRCC surgery with adjuvant chemotherapy group at stage TIN1M0 and stage T2N0M0 are both superior to that in the surgery group with statistical difference (P<0.05). In addition, the five-year survival rate of SRCC surgery with adjuvant chemotherapy group at T2N0M0 is superior to that in the non SRCC patients, with statistical difference (P<0.05). Conclusion SRCC patients present with unique clinicopathologic features. Early detection and treatment could improve the prognosis of SRCC patients.
RESUMO
Objective To review the surgical managements of patients with traumatic false aneu- rysms in the extremities.Methods From January 1990 to April 2006,17 patients with traumatic false aneurysms in the extremities were admitted into our hospital.Fourteen patients were treated by vascular repair including vascular repair in seven cases,end to end anastomosis in one,synthetic grafting in one, autogenous vein grafting in one,and direct ligation in four.Three patients were treated nonoperatively, but with local compressive dressing.Results There were no deaths or gangrenes in all cases.The clinical manifestations vanished after the treatment.The mean follow-up period was 13.2 months.The function of the injured extremities recovered satisfactorily.Conclusion Different types of traumatic false aneurysms should be managed by different therapeutic procedures after the diagnoses is made.